Roze S - Search Results

1

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M. Palmer AJ, et al. Among authors: roze s. Curr Med Res Opin. 2006 Nov;22(11):2095-100. doi: 10.1185/030079906X132730. Curr Med Res Opin. 2006. PMID: 17076969

2

A multivariate logistic regression equation to screen for diabetes: response to Tabaei and Herman.

Roze S, Palmer AJ, Valentine WJ. Roze S, et al. Diabetes Care. 2003 May;26(5):1658-9; author reply 1659. doi: 10.2337/diacare.26.5.1658. Diabetes Care. 2003. PMID: 12716861 No abstract available.

3

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ, Roze S, Annemans L, Simon TA, Chen RS, Lewis EJ; Collaborative Study Group. Rodby RA, et al. Among authors: roze s. Clin Ther. 2003 Jul;25(7):2102-19. doi: 10.1016/s0149-2918(03)80208-4. Clin Ther. 2003. PMID: 12946554

4

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. Palmer AJ, et al. Among authors: roze s. Nephrol Dial Transplant. 2003 Oct;18(10):2059-66. doi: 10.1093/ndt/gfg232. Nephrol Dial Transplant. 2003. PMID: 13679481

5

[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E. Palmer AJ, et al. Among authors: roze s. Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. doi: 10.1055/s-2004-812656. Dtsch Med Wochenschr. 2004. PMID: 14703575 German.

6

Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.

Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Palmer AJ, et al. Among authors: roze s. Clin Ther. 2004 Feb;26(2):304-21. doi: 10.1016/s0149-2918(04)90029-x. Clin Ther. 2004. PMID: 15038953

7

An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW. Palmer AJ, et al. Among authors: roze s. J Hum Hypertens. 2004 Oct;18(10):733-8. doi: 10.1038/sj.jhh.1001729. J Hum Hypertens. 2004. PMID: 15116142 Clinical Trial.

8

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.

Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH. Palmer AJ, et al. Among authors: roze s. Diabetes Care. 2004 Aug;27(8):1897-903. doi: 10.2337/diacare.27.8.1897. Diabetes Care. 2004. PMID: 15277414

9

[Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, de Alvaro F; Grupo de Estudio Colaborativo IDNT. Palmer AJ, et al. Among authors: roze s. Nefrologia. 2004;24(3):231-8. Nefrologia. 2004. PMID: 15283313 Free article. Spanish.

10

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Palmer AJ, et al. Among authors: roze s. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S5-26. doi: 10.1185/030079904X1980. Curr Med Res Opin. 2004. PMID: 15324513

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters